Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COTI 2

Drug Profile

COTI 2

Alternative Names: COTI-2

Latest Information Update: 28 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Critical Outcome Technologies
  • Developer Cotinga Pharmaceuticals; Northwestern University; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Thymidylate synthase modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Li-Fraumeni syndrome; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 28 Feb 2021 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Recurrent) in Canada (PO)
  • 28 Apr 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
  • 28 Apr 2020 No recent reports of development identified for preclinical development in Li-Fraumeni-syndrome in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top